bendamustine hydrochloride has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (18.25) | 29.6817 |
| 2010's | 71 (56.35) | 24.3611 |
| 2020's | 32 (25.40) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hui, M | 1 |
| Leslie, LA | 1 |
| Ikeda, S; Koyama, D; Misawa, K; Sukegawa, M; Suzuki, M; Teshirogi, M; Tsunoda, S | 1 |
| Chen, D; Chen, Y; Gao, J; Jia, Y; Tao, H; Wang, F; Wu, P; Zhou, Z | 1 |
| Andriani, A; Autore, F; Cimino, G; Del Poeta, G; Ditto, C; Fresa, A; Innocenti, I; Laurenti, L; Maglione, R; Mauro, FR; Mengarelli, A; Padua, L; Papa, E; Pelliccia, S; Principe, MID; Romeo, A; Stefanizzi, C; Tafuri, A | 1 |
| Belada, D; Benesova, K; Duras, J; Hanackova, V; Janikova, A; Karban, J; Mocikova, H; Obr, A; Prochazka, V; Steinerova, K; Sykorova, A; Trneny, M; Vodicka, P | 1 |
| Kawasaki, N; Nishito, Y; Yoshimura, Y; Yoshiura, S | 1 |
| Edina, BC; Rinaldi, I | 1 |
| Frascione, PMM; Novo, M; Paruzzo, L; Poletto, S; Vitolo, U | 1 |
| Kameoka, Y | 1 |
| Aisa, Y; Ito, C; Kadota, S; Kurosawa, S; Nakayama, H; Nakazato, T; Okubo, S; Sakurai, A; Shinmura, K | 1 |
| Cen, H; Ding, K; Gao, Y; Huang, H; Lin, J; Liu, Y; Lv, F; Ma, L; Song, B; Tang, X; Wang, S; Wang, Y; Wu, D; Wu, J; Xiang, Y; Xu, W; Yang, Y; Ye, X; Yu, H; Zhang, F; Zhang, Q; Zhao, Y; Zhou, J | 1 |
| DiMaria, E; Drennan, IR; Gerard, L; Kotchetkov, R; Nay, D; Prica, A; Susman, D | 1 |
| Cordoba, R; Fleury, I; Greil, R; Hess, G; Joffe, E; Kim, K; Ku, M; Kurukulasuriya, NC; Marks, R; Mondello, P; Nowakowski, GS; Peters, A; Sabatelli, L; Salles, G; Sporchia, A; Trotman, J; Waltl, EE; Winderlich, M; Yoon, DH; Zinzani, PL | 1 |
| Du, KX; Li, JY; Li, Y; Liang, JH; Shen, HR; Wang, L; Wu, JZ; Xia, Y; Xu, W; Yin, H | 1 |
| Aktar, SJ; Ante, Z; Chan, KKW; Cheung, MC; Liu, N; Prica, A; Suleman, A | 1 |
| Kodama, Y; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Urabe, S; Uraisami, K; Wada, J | 1 |
| Doki, N; Haraguchi, K; Hayashi, Y; Ishimine, K; Kanemasa, Y; Kobayashi, T; Mino, M; Morita, Y; Najima, Y; Nakamura, S; Ohashi, K; Ohigashi, A; Okuya, T; Okuyama, Y; Sasaki, Y; Shimizu, H; Shimizuguchi, T; Shimoyama, T; Shingai, N; Tamura, T; Toya, T; Yagi, Y | 1 |
| Jakobs, F; Kron, F; Kurte, MS; Reinhardt, HC; Siefen, AC; von Tresckow, B | 1 |
| Belada, D; Cheson, BD; Fingerle-Rowson, G; Gribben, J; Harbron, C; Hoster, E; Kahl, B; Kehden, B; Mundt, K; Nicolas-Virelizier, E; Pott, C; Sehn, LH; Spielewoy, N; Wassner-Fritsch, E | 1 |
| Dixon, BN; Ni, A; Sarlo, KM; Straus, DJ | 1 |
| Bovo, C; Krampera, M; Quaglia, FM; Tisi, MC; Visco, C | 1 |
| Cho, SH; Chung, JS; Jo, JC; Kim, DY; Shin, HJ | 1 |
| Arcaini, L; Arcari, A; Bergamini, F; Bertù, L; Bianchi, B; Bolis, S; Cencini, E; Cocito, F; Defrancesco, I; Fabbri, N; Farina, L; Ferrario, A; Gentile, M; Gini, G; Goldaniga, M; Greco, A; Loseto, G; Luminari, S; Merli, M; Molinari, AL; Mora, B; Passamonti, F; Rossi, FG; Saturni, V; Scapinello, G | 1 |
| Akiba, K; Hashida, T; Hirano, T; Hosohata, K; Ikesue, H; Ishikawa, T; Maegawa, N; Miyasaka, M; Mori, Y; Muroi, N; Nakamura, T; Shimomura, Y; Takano, A; Uchida, M; Yamaguchi, Y | 1 |
| Alpdogan, SO; Carabasi, M; Chapman, A; DiMeglio, M; Filicko-OHara, J; Flomenberg, N; Gaballa, S; Ghimire, S; Gong, J; Martinez-Outschoorn, U; Pan, J; Porcu, P; Pro, B; Ramirez, M; Rose, L; Wagner, JL; Weiss, M | 1 |
| Boyd, TE; Cannan, M; Fellague-Chebra, R; Feng, X; Kingsley, E; Lyons, RM; Moezi, M; Richards, D; Sharman, J; Shtivelband, M | 1 |
| Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ | 1 |
| Abraham, I; Bartels, T; Kumar, A; McBride, A; Moore, L; Persky, DO | 1 |
| Du, X; Han, XH; Hellriegel, E; Hong, XN; Huang, HQ; James, L; Jia, YQ; Jin, J; Ke, XY; Li, W; Liu, AC; Liu, DH; Shen, ZX; Shi, YK; Wu, DP; Wu, JQ; Xiao, XB; Xu, W; Yang, JL; Yang, SM; Zhang, LS; Zhang, MZ; Zhou, DB; Zhu, J | 1 |
| Babanrao Pisal, C; Davis, J; Friedberg, JW; Izquierdo, M; Janssens, A; Keating, MM; Lasher, J; MacDonald, D; Rummel, MJ; Zaucha, JM | 1 |
| Baek, GT; Brown, A; Marini, BL; Mathis, NJ; Nachar, VR; Perissinotti, AJ; Phillips, TJ; Wilcox, RA | 1 |
| Bar, MH; Bartlett, NL; Cabanillas, F; Chen, Z; Cheson, BD; Dodds, AJ; Ellis, T; Friedberg, JW; Ganjoo, KN; Herst, J; Joyce, R; LaCasce, AS; Lemieux, B; Leonard, JP; Martin, P; Montgomery, PG; Pressnail, B; Rajguru, SA; Robinson, KS; Smith, MR; Szer, J; van der Jagt, RH; VanderWalde, A; Williams, M | 1 |
| Anthony, SP; Chanas, B; Cheung, EM; Edenfield, WJ; Hepner, A; Mattar, B; Mutch, PJ; Smith, M | 1 |
| Brown, JR; Danilov, AV; Gordon, MJ; Lewis, LD | 1 |
| Aotsuka, N; Igarashi, T; Irisawa, H; Itoh, K; Masuda, S; Tsujimura, H; Tsukasaki, K; Utsu, Y; Wakita, H | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Blanco, LZ; Horowitz, JM; Kanis, MJ; Karmali, R; Lurain, JR; Peevey, J; Zielenbach, M | 1 |
| Akashi, K; Hosohata, K; Ikesue, H; Kato, K; Makihara, Y; Miyamoto, T; Mori, Y; Nakamura, T; Shiratsuchi, M; Suetsugu, K; Uchida, M | 1 |
| Farmakiotis, D; Freedman, A; Fung, M; Gu, X; Jacobsen, E; Koo, S; Nguyen, PL; Prestes, D | 1 |
| Cragg, MS; Sopp, J | 1 |
| Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L | 1 |
| Burke, JM; Chang, J; Chen, L; Flinn, IW; Hallman, D; Hawkins, T; Issa, S; Kahl, B; Kolibaba, K; MacDonald, D; Simpson, D; Trotman, J; van der Jagt, R; Wood, P | 1 |
| Blajer-Olszewska, B; Chojnacki, T; Drozd-Sokołowska, J; Długosz-Danecka, M; Hus, I; Jurczak, W; Jurczyszyn, A; Puła, B; Raźny, M; Romejko-Jarosińska, J; Taszner, M | 1 |
| Bogeljić Patekar, M; Kursar, M; Mandac Rogulj, I; Milunović, V; Mišura Jakobac, K; Ostojić Kolonić, S; Perica, D; Planinc-Peraica, A | 1 |
| Chen, W; Li, JJ; Sadeghi, N | 1 |
| Gribben, J | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Broome, CM; Cheson, BD; McCloskey, JK | 1 |
| Ogura, M | 1 |
| Brugger, W; Ghielmini, M | 1 |
| Beygi, H; Engle, R; Knopf, KB; Nordstrom, BL; Sterchele, JA; Teltsch, DY | 1 |
| Cordes, SF; Liang, JJ; Witzig, TE | 1 |
| van der Jagt, R | 1 |
| Castaigne, JG; Dewilde, S; Dunlop, W; Parker, C; Woods, B | 1 |
| Butrym, A; Dmoszynska, A; Dzietczenia, J; Gorska-Kosicka, M; Grzegorz, M; Hus, I; Jawniak, D; Jedrzejczak, WW; Krawczyk-Kulis, M; Kyrcz-Krzemien, S; Lech-Maranda, E; Poplawska, L; Walewski, J; Warzocha, K; Waszczuk-Gajda, A; Wrobel, T | 1 |
| Burke, JM; Chen, L; Clementi, R; Craig, M; Flinn, IW; Hallman, DM; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; Kwan, YL; Macdonald, D; Munteanu, M; Simpson, D; van der Jagt, R; Wood, P | 1 |
| Bond, M; Burke, JM; Darwish, M; Hellriegel, E; Ludwig, E; Munteanu, MC; Phillips, L; Robertson, P | 1 |
| Baumann, FT; Bloch, W; Elter, T; Fiebig, L; Hahn, M; Hallek, M; Hülsdünker, T; Mierau, A; Reinart, N; Schenk, A; Strüder, HK; Zimmer, P | 1 |
| Gil, L; Kazmierczak, M; Komarnicki, M; Kroll-Balcerzak, R | 1 |
| Boehme, A; Brendel, K; Dreyling, M; Fingerle-Rowson, G; Fischer, R; Gonnermann, M; Höhler, T; Kegel, T; Kellermann, L; Nusch, A; Pönisch, W; Schmidt, C; Wendtner, C | 1 |
| García Muñoz, R; Izquierdo-Gil, A; Muñoz, A; Panizo, C; Rabasa, P; Roldan-Galiacho, V | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Chen, PM; Chiou, TJ; Hou, HA; Hsiao, LT; Kuo, CY; Liu, CY; Tien, HF; Wang, MC; Wu, JH | 1 |
| Blum, KA; Byrd, JC; Christian, B; Flynn, J; Jaglowski, S; Jenkins, C; Jones, JA; Lozanski, G; Maddocks, K; Porcu, P; Wei, L | 1 |
| Caballero, MD; Capria, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Gobbi, M; Gonella, R; Isidori, A; Loscocco, F; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Specchia, G; Stefani, PM; Visani, G | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Cheson, BD; Crawford, J | 1 |
| Burke, JM; Chen, L; Craig, MD; Flinn, IW; MacDonald, DA; Morganroth, J; Munteanu, MC; van der Jagt, RH | 1 |
| Abhayankar, S; Aljitawi, O; Diaz, F; Divine, C; Ganguly, S; Iliff, A; McGuirk, J | 1 |
| Fernandez, SG; Miranda, JJ | 1 |
| Arcaini, L; Baldini, L; Carella, AM; Cesaretti, M; Goldaniga, M; Luminari, S; Orsucci, L; Pinto, A; Pulsoni, A; Salvi, F; Stelitano, C; Tedeschi, A; Tucci, A | 1 |
| Aurran, T; Blaise, D; Bouabdallah, R; Broussais, F; Chabannon, C; Coso, D; Garciaz, S; Helvig, A; Schiano de Collela, JM; Stoppa, AM; Xerri, L | 1 |
| Burke, JM; Craig, M; Flinn, IW; Hawkins, TE; Hertzberg, M; Issa, S; Kahl, BS; Kolibaba, K; MacDonald, D; Munteanu, M; Simpson, D; van der Jagt, RH; Victor, TW; Wood, P | 1 |
| Cuzzocrea, S; Ferrero, S; Ghione, P; Mauro, E; Mian, M; Mondello, P; Pitini, V; Steiner, N; Visentin, A; Wasle, I; Willenbacher, W; Zaja, F; Zambello, R | 1 |
| Bouabdallah, K; Cheson, BD; Chua, N; Delwail, V; Dimier, N; Dueck, G; Fingerle-Rowson, G; Fowler, N; Gribben, J; Lennard, A; Lugtenburg, PJ; Mayer, J; Press, O; Salles, G; Sehn, LH; Trněný, M; Wassner-Fritsch, E | 1 |
| Hamlin, PA | 1 |
| Munakata, W; Tobinai, K | 1 |
| Catalano, L; Cerchione, C; De Renzo, A; Della Pepa, R; Di Perna, M; Pane, F; Picardi, M; Pugliese, N | 1 |
| Cheson, BD; Dimier, N; Gribben, JG; Kimby, E; Launonen, A; Lugtenburg, PJ; Sehn, LH; Thieblemont, C; Trask, PC; Wassner-Fritsch, E | 1 |
| Alrifai, T; Grant Szymanski, K; Karmali, R; Mahon, B; Okwuosa, T; Venugopal, P | 1 |
| Cheson, BD | 2 |
| Carter, NJ; Plosker, GL | 1 |
| Masiello, D; Tulpule, A | 1 |
| Wilkes, GM | 1 |
| Bargetzi, M; Heizmann, M; Kotrubczik, N; Moosmann, P; Wernli, M | 1 |
| Cheson, BD; Kroll, ML | 1 |
| D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA | 1 |
| Cheson, BD; Dreyling, M; Friedberg, J; Gribben, J; Hoelzer, D; Knop, S; Montillo, M; Moreau, P; Pieper, A; Rummel, M; Wendtner, CM | 1 |
| Czuczman, MS; Rummel, MJ | 1 |
| Czuczman, MS; Elefante, A | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS | 1 |
| Garnock-Jones, KP | 1 |
| Cheson, BD; Ujjani, C | 1 |
| Rummel, M | 1 |
| Montillo, M; Morra, E; Ricci, F; Tedeschi, A; Vismara, E | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS; Tremmel, L; Van der Jagt, RH | 1 |
| Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Wada, T | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Arranz, R; Calleja, M; Cánovas, A; Cervera, JM; de la Fuente, I; de Oña, R; Domingo, E; Gironella, M; Gorosquieta, A; Grande, C; Guillén, H; Lopez-Lorenzo, JL; Marin, M; Medina, A; Mencha, C; Panizo, C; Peñalver, FJ; Perez, I; Perez, R; Prieto, E; Ramila, E; Salar, A; Sanchez-Gonzalez, B; Sancho, JM; Sebastian, E | 1 |
| Chan, M; Detroye, A; Ellis, T; Johnson, A; Lesser, GJ; McMullen, K; Mott, R; Renfrow, JJ; Tatter, S | 1 |
| Balzarotti, M; Bongarzoni, V; Bosi, A; Carpaneto, A; Cortelazzo, S; D'Arco, A; Freilone, R; Gaidano, G; Gobbi, M; Iannitto, E; Liberati, AM; Orciuolo, E; Patti, C; Piccin, A; Puccini, B; Rigacci, L; Rota-Scalabrini, D; Storti, S; Zaja, F; Zinzani, PL | 1 |
| Asaka, M; Imamura, M; Miyashita, N; Ogasawara, R; Tanaka, J; Tsutsumi, Y | 1 |
| Bighin, C; Del Mastro, L; Gardin, G; Giraudi, S; Lambertini, M; Levaggi, A; Pronzato, P | 1 |
| Ackler, S; Boghaert, ER; Chen, J; Clarin, J; Foster, K; Jin, S; Leverson, JD; Mitten, MJ; Phillips, DC; Schlessinger, S; Wang, B | 1 |
| Hoy, SM | 1 |
| Cheson, BD; Diehl, V | 1 |
| Chow, KU; Hoelzer, D; Mitrou, PS; Rummel, MJ; Weidmann, E | 1 |
| Hoelzer, D; Mitrou, PS; Rummel, MJ | 1 |
| Hoelzer, D; Kim, SZ; Mitrou, PS; Rost, A; Schuppert, H; Seipelt, G; Weidmann, E | 1 |
| Bremer, K | 1 |
| Al-Batran, SE; Chow, KU; Dürk, H; Hansmann, ML; Hecker, R; Hoelzer, D; Josten, KM; Kim, SZ; Kofahl-Krause, D; Mitrou, PS; Neise, M; Rost, A; Rummel, MJ; von Grünhagen, U; Welslau, M | 1 |
| Arzberger, H; Boewer, C; Bremer, K; Dachselt, K; Franke, A; Freund, M; Fricke, HJ; Hahnfeld, S; Herold, M; Ismer, B; Klinkenstein, C; Müller, C; Niederwieser, D; Pasold, R; Richter, P; Schirmer, V; Schulze, A; Schulze, M; Schwarzer, A; Weniger, J; Winkelmann, C | 1 |
| Bertoni, F; Zucca, E | 1 |
| Aldaoud, A; Dreyling, M; Haak, U; Hess, G; Heymanns, J; Hiddemann, W; Huber, C; Köppler, H; Losem, C; Schmitz, S; Thomalla, J; Unterhalt, M; Weide, R | 1 |
| Friedberg, JW; Hagemeister, FB; Leonard, JP; Levine, AM | 1 |
| Bessudo, A; Camacho, ES; Chen, L; Cheson, BD; Cohen, P; Fayad, LE; Forero-Torres, A; Friedberg, JW; La Casce, AS; Oliver, JW; Robinson, KS; van der Jagt, RH; Williams, ME | 1 |
| Forero-Torres, A; Saleh, MN | 1 |
| Balfour, JA; Goa, KL | 1 |
| Boehrer, S; Chow, KU; Geduldig, K; Hoelzer, D; Krapohl, A; Mitrou, PS; Weidmann, E | 1 |
| Heider, A; Niederle, N | 1 |
28 review(s) available for bendamustine hydrochloride and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisone; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2022 |
Treatment strategies for patients with diffuse large B-cell lymphoma.
Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Receptors, Chimeric Antigen; Rituximab; Vincristine | 2022 |
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Topics: Antigens, CD19; Bendamustine Hydrochloride; Cost-Effectiveness Analysis; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Comorbidity; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Treatment Outcome | 2017 |
BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Topics: Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Child; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Medication Therapy Management | 2018 |
Rituximab plus bendamustine for the treatment of aggressive non-hodgkin lymphoma patients with severe liver impairment.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Liver Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2013 |
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Cyclophosphamide; Germany; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Practice Guidelines as Topic; Rituximab | 2013 |
Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2013 |
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prognosis | 2014 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Design; Drug Discovery; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab; Stroke Volume; Treatment Outcome | 2017 |
Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Resistance, Neoplasm; Half-Life; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Nitrogen Mustard Compounds; Rituximab | 2008 |
Bendamustine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Drug Tolerance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Nitrogen Mustard Compounds | 2009 |
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2010 |
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2010 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Nitrogen Mustard Compounds | 2010 |
[Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2011 |
Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Retrospective Studies | 2012 |
Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prednisolone; Prognosis; Remission Induction; Rituximab; Survival Rate; Vincristine | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Combination treatment approaches and novel therapies for lymphoma.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cancer Vaccines; Cytokines; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Stem Cell Transplantation | 2007 |
Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War.
Topics: Alkylating Agents; Antimetabolites; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2007 |
Bendamustine.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Breast Neoplasms; Female; Half-Life; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Nitrogen Mustard Compounds | 2001 |
31 trial(s) available for bendamustine hydrochloride and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Rituximab | 2022 |
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Busulfan; Combined Modality Therapy; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Premedication; Progression-Free Survival; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2020 |
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Carboplatin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy | 2021 |
Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Rituximab | 2021 |
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oligopeptides; Prognosis; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2021 |
Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; China; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prospective Studies; Rituximab | 2021 |
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Survival Rate | 2021 |
Safety and Pharmacokinetics of Bendamustine Rapid-Infusion Formulation.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Bendamustine Hydrochloride; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Humans; Injection Site Reaction; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Therapeutic Equivalency | 2017 |
Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Biomarkers; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2018 |
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides | 2018 |
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Progression-Free Survival; Proportional Hazards Models; Rituximab; Survival Rate; Vincristine | 2019 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Nitrogen Mustard Compounds; Paresthesia; Peripheral Nervous System Diseases; Prednisone; Rituximab; Treatment Outcome; Vincristine; Vomiting | 2014 |
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Female; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prognosis; Taiwan | 2015 |
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Young Adult | 2015 |
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Nitrogen Mustard Compounds; Transplantation, Autologous | 2014 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Electrocardiography; Female; Heart Rate; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2015 |
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Progression; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Remission Induction; Rituximab; Treatment Outcome | 2016 |
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Quality of Life; Rituximab; Surveys and Questionnaires; Vincristine | 2016 |
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Rituximab; Survival Rate | 2016 |
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Quality of Life; Rituximab; Treatment Outcome | 2017 |
Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2010 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Survival Rate; Treatment Outcome | 2002 |
High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2002 |
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Risk Assessment; Rituximab; Single-Blind Method; Survival Rate; Treatment Outcome | 2005 |
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome | 2008 |
Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Survival Analysis | 2001 |
67 other study(ies) available for bendamustine hydrochloride and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Indolent T cell lymphoma involving the central nervous system and successfully treated by bendamustine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Nitrogen Mustard Compounds; Rituximab | 2022 |
Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.
Topics: Agammaglobulinemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoglobulin G; Lymphocyte Count; Lymphoma, Non-Hodgkin; Lymphopenia; Retrospective Studies; Rituximab | 2022 |
Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Gastroscopy; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome; Ultrasonography | 2022 |
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Rituximab | 2022 |
[Standard treatment and future perspectives for follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Quality of Life; Rituximab | 2022 |
Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neurolymphomatosis; Rituximab | 2023 |
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2023 |
Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Rituximab | 2023 |
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large
Topics: Adolescent; Adult; Bendamustine Hydrochloride; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab | 2023 |
[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, Non-Hodgkin; Ontario; Prednisone; Retrospective Studies; Rituximab; Vincristine | 2023 |
Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell- and Tissue-Based Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab | 2023 |
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Rituximab | 2020 |
Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Incidence; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab | 2020 |
Bendamustine plus rituximab: is it a BRIGHT idea?
Topics: Bendamustine Hydrochloride; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Rituximab | 2020 |
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Rituximab | 2020 |
Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Resistance, Neoplasm; Female; Humans; Incidence; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Assessment; Risk Factors; Rituximab | 2020 |
Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Treatment Outcome | 2021 |
Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Lymphoma, Non-Hodgkin; Retrospective Studies; Rituximab | 2021 |
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Time Factors; Treatment Outcome | 2017 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma.
Topics: Antigens, CD20; Antineoplastic Agents; Bendamustine Hydrochloride; Biomarkers, Tumor; Biopsy; Female; Histocytochemistry; Humans; Immunohistochemistry; Leukosialin; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Microscopy; Middle Aged; Rituximab; Treatment Outcome; Vulva; Vulvar Neoplasms | 2018 |
Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Bendamustine Hydrochloride; Dexamethasone; Female; Granisetron; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Palonosetron; Retrospective Studies; Vomiting | 2018 |
Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Female; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Multivariate Analysis; Risk Factors | 2019 |
Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies.
Topics: Antibodies, Monoclonal, Humanized; B-Lymphocytes; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Rituximab | 2018 |
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Transplantation, Autologous | 2019 |
Conjunctival lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Conjunctival Neoplasms; Humans; Lymphoma, Non-Hodgkin; Rituximab | 2019 |
Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2013 |
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Liver Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2013 |
The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Creatinine; Databases, Factual; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2014 |
More than skin-deep.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Lymphoma, Non-Hodgkin; Male; Nail Diseases; Nitrogen Mustard Compounds; Oral Ulcer; Paraneoplastic Syndromes; Pemphigus; Rituximab; Weight Loss | 2013 |
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; England; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rituximab; Vincristine; Wales | 2014 |
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab; Thrombocytopenia | 2013 |
An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Interactions; Female; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2014 |
Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab a
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Brain-Derived Neurotrophic Factor; Cognition Disorders; Cyclophosphamide; Doxorubicin; Electroencephalography; Fatigue; Female; Humans; Interleukin-6; Lymphoma, Non-Hodgkin; Male; Middle Aged; Outcome Assessment, Health Care; Prednisone; Rituximab; Surveys and Questionnaires; Vincristine | 2015 |
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Rituximab; Young Adult | 2015 |
Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-Positive T-Lymphocytes; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab; Treatment Outcome | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
A Second Anti-CD20 Drug for NHL.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome | 2015 |
Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine.
Topics: Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cells; Recurrence; Transplantation, Autologous; Treatment Outcome | 2016 |
Bendamustine reactivates latent Epstein-Barr virus.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Herpesvirus 4, Human; Humans; Lymphoma, Non-Hodgkin; Virus Activation; Virus Latency | 2016 |
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.
Topics: Adult; Aged; Autografts; Bendamustine Hydrochloride; Female; Humans; Kidney Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning | 2016 |
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vincristine | 2016 |
Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Febrile Neutropenia; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Rituximab | 2017 |
Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vincristine | 2008 |
Bendamustine (Treanda) for CLL and NHL.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds | 2008 |
Drug essentials. An alkylating agent for CLL and NHL.
Topics: Alkylating Agents; Antineoplastic Agents; Bendamustine Hydrochloride; Fatigue; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Patient Education as Topic | 2009 |
Bendamustine induced neurotoxicity.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brain; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neurotoxicity Syndromes; Nitrogen Mustard Compounds | 2009 |
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Time Factors; Treatment Outcome | 2010 |
Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Survival Analysis | 2010 |
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide | 2010 |
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Nausea; Nitrogen Mustard Compounds; Rituximab; Survival Analysis; Treatment Outcome | 2010 |
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Compassionate Use Trials; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Invasiveness; Nitrogen Mustard Compounds; Retrospective Studies; Spain; Treatment Outcome | 2012 |
Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds | 2012 |
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Foundations; Humans; Italy; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Middle Aged; Multicenter Studies as Topic; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Rituximab; Societies, Medical; Survival Analysis; Treatment Failure | 2012 |
HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2012 |
Bendamustine: inadequate or outdated data.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic | 2012 |
Stevens-Johnson syndrome after treatment with bendamustine.
Topics: Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Hepatitis C; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Stevens-Johnson Syndrome | 2012 |
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Topics: Aniline Compounds; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Line, Tumor; Humans; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Nitrogen Mustard Compounds; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Bendamustine in the treatment of hematologic malignancies. Introduction.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds | 2002 |
In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Carcinoma; Complement System Proteins; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Rituximab; Tumor Cells, Cultured | 2002 |
[A new highly effective therapy of indolent non-Hodgkin lymphomas with bendamustin].
Topics: Animals; Austria; Bendamustine Hydrochloride; Germany; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Survival Rate; Treatment Outcome | 2003 |
Bendamustine in lymphomas: more to combine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Treatment Outcome | 2007 |
In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Tumor Cells, Cultured | 2001 |